Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.

Cost Dynamics of Jazz vs. Supernus: A Decade in Review

__timestampJazz Pharmaceuticals plcSupernus Pharmaceuticals, Inc.
Wednesday, January 1, 20141174180005758000
Thursday, January 1, 20151025260008423000
Friday, January 1, 201610538600011986000
Sunday, January 1, 201711018800015215000
Monday, January 1, 201812154400015356000
Tuesday, January 1, 201912793000016660000
Wednesday, January 1, 202014891700052459000
Friday, January 1, 202144076000075061000
Saturday, January 1, 202254051700087221000
Sunday, January 1, 202343557700083779000
Loading chart...

Unveiling the hidden dimensions of data

Analyzing Cost of Revenue: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, understanding cost dynamics is crucial. Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc. have shown distinct trajectories in their cost of revenue from 2014 to 2023. Jazz Pharmaceuticals experienced a staggering 360% increase in cost of revenue, peaking in 2022. This surge reflects their aggressive expansion and investment in new drug development. In contrast, Supernus Pharmaceuticals, Inc. maintained a more conservative growth, with costs rising by approximately 1,400% over the same period, indicating a strategic focus on scaling operations. Notably, 2021 marked a pivotal year for both companies, with Jazz's costs soaring by 196% compared to the previous year, while Supernus saw a 43% increase. These trends underscore the diverse strategies employed by these industry players, offering insights into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025